Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
about
Antiangiogenic therapy for high-grade gliomaHigh-grade glioma management and response assessment-recent advances and current challengesChallenges of Using High-Dose Fractionation Radiotherapy in Combination TherapyImmune Evasion Strategies of GlioblastomaConcurrent therapy to enhance radiotherapeutic outcomes in glioblastomaA Systematic Review on the Characteristics, Treatments and Outcomes of the Patients with Primary Spinal Glioblastomas or Gliosarcomas Reported in Literature until March 2015VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedsideAdvances in the treatment of newly diagnosed glioblastomaTherapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future directionBevacizumab for glioblastomaRadio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical ApplicationsRisk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-AnalysisNonsurgical treatment of recurrent glioblastomaTargeting Aggressive Cancer Stem Cells in GlioblastomaCombining radiotherapy with sunitinib: lessons (to be) learnedConsensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trialsMolecular characterizations of glioblastoma, targeted therapy, and clinical results to dateBevacizumab in Japanese patients with malignant glioma: from basic research to clinical trialNF-κB and STAT3 in glioblastoma: therapeutic targets coming of ageCurrent standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patientsTargeted molecular therapies against epidermal growth factor receptor: past experiences and challengesImmunotherapy advances for glioblastomaMedical management of brain tumors and the sequelae of treatment.Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapyCombinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current statusPolymeric drug delivery for the treatment of glioblastomaEphs and Ephrins in malignant gliomasTrial watch: Dendritic cell-based anticancer therapyTo what extent will 5-aminolevulinic acid change the face of malignant glioma surgery?Movement of magnetic nanoparticles in brain tissue: mechanisms and impact on normal neuronal functionAfatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.Therapeutic Potential of Curcumin for the Treatment of Brain TumorsImmunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Prospects of immune checkpoint modulators in the treatment of glioblastomaGlioblastoma multiforme: emerging treatments and stratification markers beyond new drugsWhat next for newly diagnosed glioblastoma?The Role of Glucose Modulation and Dietary Supplementation in Patients With Central Nervous System TumorsHeat shock protein vaccines against glioblastoma: from bench to bedsideInfluence of glioblastoma contact with the lateral ventricle on survival: a meta-analysisSelf-assembled 20-nm (64)Cu-micelles enhance accumulation in rat glioblastoma
P2860
Q24193485-3A7CD5CD-B5C5-4291-8216-0232971FC876Q26740664-32A8D3C7-D84B-4DED-8D21-E2DF1CAB5BE7Q26742107-90D352C3-F4AF-48E1-8B1E-FF9CF37A0D15Q26765855-9E486F75-E735-45E0-B43B-9869039CFE89Q26767169-73E9E81E-8558-4CDB-9E89-7820E6882B1FQ26767359-1090653F-5FB2-41A5-BDDD-77DE10E41BF1Q26770678-D732873A-B571-4F35-928E-F9BB04A1C1E8Q26773514-5516E22B-9743-4CD7-AD6F-FCE4D95DB0A9Q26774717-4758BA37-692B-45B7-94D2-709ACB11C56EQ26776307-FB1B0BE0-9109-4EC8-AE94-C49339E21C47Q26779221-087A60F0-2B3E-453B-8864-32AD4AA6C9EAQ26783779-A865681F-ABB8-4670-8E05-CF4D8D6F1BDBQ26795560-F4DB3615-F2D9-4996-AB62-FEB4A218D900Q26799983-2AE9D069-36D2-40A8-864F-E1A335F27F4DQ26800587-B3F7D42E-3C11-419A-A324-1225CACAD878Q26801351-3638729E-AA32-4A50-9F65-D240925F3619Q26822717-394EDD88-8B32-4BDB-96E7-5CB74817C9C3Q26824777-F79E852C-09C6-4DDF-927C-4BEFF8C76C40Q26830388-D01BC7AD-CF1E-4565-8981-8FC90FBD4B23Q26853308-DA095DAA-726D-49F4-815D-AFCBBDE0524BQ26862516-7A78C2C5-3263-4D01-92EB-AD9CEB716744Q26866513-D4ED42D4-A622-485E-814B-D0AE368637CDQ26992174-77AF9F01-055E-46F6-90CC-AE0DC7A80F57Q26998111-E38643B2-F046-4529-83E9-7FB25E00B5F9Q27001560-723AD0AF-A8EF-4438-A82C-B5B10F5CF875Q27010046-9E14308D-1925-443A-8F5D-E56E18929791Q27015780-2173EC48-F4E4-49DF-9721-18BF6F1309E6Q27024047-45805850-7F0A-4C71-BEB6-E7FD1AE5056EQ27028189-FC1E2A0F-153F-4EF8-9860-C0AAF96060A0Q27308522-820EB7CB-7DC8-4923-9EE3-A16D6AD6999CQ27853219-791F1987-FBAA-496B-B67A-647159983EADQ28071572-30996754-E640-4C9D-863B-AB679620C501Q28078539-3E9DAF90-8601-4ECB-9CDE-D4607F52FC4AQ28081371-36B4B8BE-97C2-42DA-BEE8-345C1B76B463Q28082603-133755C2-B702-4871-8C5D-0FBA77AF6F63Q28086839-73F6FAAA-6FEB-4041-AF8F-516059EC7CD7Q28087476-38B84A35-ACEB-416D-B1F3-E9EA0CA5E3CAQ28087775-D8E5B855-3A7D-485E-AACD-A41E230FB51AQ28278674-1D90F0EC-8D09-4D69-94F8-ADF2A238E1A0Q28603646-D1FA69B9-0388-434D-A61F-C4161165A903
P2860
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
@en
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
@nl
type
label
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
@en
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
@nl
prefLabel
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
@en
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
@nl
P2093
P50
P356
P1476
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
@en
P2093
Antoine F Carpentier
Dana Cernea
Frank Saran
Khe Hoang-Xuan
Lauren Abrey
Magalie Hilton
Petr Kavan
Roger Henriksson
Ryo Nishikawa
Timothy Cloughesy
P304
P356
10.1056/NEJMOA1308345
P407
P577
2014-02-01T00:00:00Z